MedTrace Logo

Analytical Treatment Interruption in HIV Positive Patients

NCT02590354 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2019-09-24

Study results available
· View outcomes & findings →

Summary

HIV-1 infected patients with normal peripheral blood CD4+ T-cell counts and undetectable viral load will be recruited in four Belgian HIV reference centers. Selected patients will undergo a two-step screening in which a viral reservoir measurement will be performed and among those with a very low viral reservoir an analytical treatment interruption of their longstanding antiretroviral therapy (ART). There is no randomization foreseen. Patients will receive an intense clinical and laboratory follow-up during 48 weeks followed by 12 weeks post intervention.

Conditions

  • HIV-1 Infection

Interventions

OTHER

ART interruption

Sponsors & Collaborators

  • University Hospital, Ghent

    collaborator OTHER

  • Universitair Ziekenhuis Brussel

    collaborator OTHER

  • Saint-Pierre University Hospital

    collaborator OTHER

  • Agentschap voor Innovatie door Wetenschap en Technologie

    collaborator OTHER

  • Institute of Tropical Medicine, Belgium

    lead OTHER

Principal Investigators

  • Eric Florence, Dr · Institute of Tropical Medicine

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-25
Primary Completion
2018-06-22
Completion
2018-06-22

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02590354 on ClinicalTrials.gov